Active Clinical Trials for Prostate Cancer


This page lists many active clinical trials (protocols) at Fox Chase Cancer Center for Prostate cancer. In addition to the title, some studies below have brief summaries.

Clinical trials, or protocols, are research studies conducted with people who volunteer to take part. You benefit by having access to new cancer treatments and options not otherwise available, in addition to the excellent care offered at Fox Chase.

For more information on clinical trials at Fox Chase Cancer Center, or to find a study, call 1-888 FOX CHASE (1-888-369-2427).
Open DateTrial NumberPrincipal InvestigatorTitle
09/18/2003IRB03835/03-835Eric Horwitz Prospective Collection Of Characteristics And Outcome Of Patients Treated For Prostate Cancer At Fox Chase Cancer Center
02/27/2012IRB11825/11-825Suzanne Miller Randomized Controlled Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS - PRostate Cancer Online Guide & Resources for Electronic Survivorship Service)
11/19/1996IRB96091/96-091Elias Obeid Prostate Cancer Risk Assessment Program
07/17/2014BM-018/13-838Joshua Meyer A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
11/11/2015PSOTIO001/13-056Matthew Zibelman A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
12/10/2013IRB13846/13-846Elias Obeid Genetic Evaluation Of Men - The GEM Registry
11/16/2012IRB12861/12-861Elias Obeid Hereditary Cancer Syndromes In Families of Men with Prostate Cancer In A Genetic Counseling Setting
08/04/201414-036/14-036Nestor Esnaola A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-Based, Protocol-Driven Management in Patients Undergoing Major Cancer Surgery
01/13/2015C28002/14-054Anthony Olszanski A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination with MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients with Advanced Nonhematologic Malignancies
01/14/200908854/08-854Elias Obeid The role of genetic variants at chromosomal loci 8q and 17q in prostate cancer screening in African American men and men with a family history of prostate cancer
09/04/201515-1001/15-1001Marc Smaldone A Prospective, Multi-Institutional, Randomized, Phase II Trial of Best Systemic Therapy (BST) or Best Systemic Therapy Plus Definitive Treatment (Radiation or Surgery) of the Primary Tumor in Metastatic (M1) Prostate Cancer
09/01/201615-1009/15-1009Anthony Olszanski A Phase I Dose-Escalation Study of ONC201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
05/15/201515-9018/15-9018Marc Smaldone Pennsylvania Urologic Regional Collaborative
12/01/201515-1015/15-1015Daniel Geynisman Bicalutamide with or without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients (BIMET-1)
07/28/201515-9022/15-9022Eric Horwitz Short term complications in prostate brachytherapy, active surveillance, and prostatectomy.
10/28/201515-7002/15-7002Lori Goldstein Molecular Analysis for Therapy Choice (MATCH)
10/26/201616-1056/16-1056Namrata Vijayvergia A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients with Metastatic High Grade Neuroendocrine Tumors
06/20/201616-1018/16-1018Anthony Olszanski A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors
07/11/201616-8002/16-8002Michael Hall Association of Baseline Nutritional Status with Toxicity and Outcomes in Early Phase Trial Participants
01/13/201716-1043/16-1043Alexander Kutikov REASSURE ME
01/16/201716-2004/16-2004Matthew Philp Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction.
05/16/201716-1060/16-1060Philip Pancari A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
02/10/201716-1074/16-1074David Chen A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS)
06/21/201716-1071/16-1071Anthony Olszanski A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors
01/05/201716-1073/16-1073Anthony Olszanski Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
05/06/201615-1081/15-1081Wafik El-Deiry A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
06/23/201717-1008/17-1008Daniel Geynisman A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, Relative to Placebo plus Abiraterone plus Prenisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic Castrate-Resistant Prostate Cancer